Skip to main content

aripiprazole

Generic: ARIPIPRAZOLE·Brand: ABILIFY, ABILIFY ASIMTUFII, ABILIFY MAINTENA KIT, ABILIFY MYCITE KIT, ARIPIPRAZOLE, Abilify, MEZOFY, OPIPZA, Opipza

aripiprazole: 4 clinical trials tracked.

aripiprazole evidence translation

What we can confirm

4 tracked trials

No verified listed developer

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about aripiprazole, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 3 study sponsors
Clinical Trials (4)

A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Monotherapy Study to Evaluate Efficacy of Roluperidone on Negative Symptoms in Adult Subjects With Schizophrenia, Followed by a 52-Week, Randomized, Double-Dummy Phase to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

NCT07565428·Phase 3·NERV
Recruiting

Primary endpoint: Change from Baseline to Week 12 in Marder Negative Symptoms Factor Score (NSFS)

InterventionalRandomizedquadruple380 targetStarted 2026-04Completion 2028-1213 sites · United StatesMinerva Neurosciences

A Prospective, Matched-Control, Randomized, Open-Label, Flexible-Dose, Study in Subjects With Recent-Onset Schizophrenia or Schizophreniform Disorder to Compare Disease Progression and Disease Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics

NCT02431702·Phase 3·BRSF
Completed

Primary endpoint: Part-2 (Disease Progression): Time to First Treatment Failure

InterventionalRandomizedopen337 enrolledStarted 2015-07Completion 2019-1138 sites · Brazil, Mexico, United StatesJanssen Scientific Affairs, LLC

REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

NCT01490086·Phase 2·RVPH
Completed

Primary endpoint: Measurement of Schizophrenia Symptoms: Positive and Negative Syndrome Scale (PANSS) Total Score

InterventionalRandomizedtriple234 enrolledStarted 2011-12Completion 2013-0315 sites · India, Malaysia, Moldova, Philippines…Reviva Pharmaceuticals

Estimating and Reducing the Cardiovascular Risk of Patients With Schizophrenia Drugs From Lipid Measures and Ischemic Electrocardiographic Changes

NCT00288353·Phase 3
Terminated

Primary endpoint: Triglyceride/High-density Lipoprotein (TG/HDL) Ratio

InterventionalRandomizedopen48 targetStarted 2006-01Completion 2008-121 site · United StatesNorthwestern University